嘉應制藥(002198.SZ):相關股東表決權委託協議及股東一致行動人協議有效期延長
格隆匯 1 月 25日丨嘉應制藥(002198.SZ)公佈,公司於今日收到公司股東陳泳洪、黃智勇、黃利兵(“甲方”)及中聯集信投資管理有限公司(“中聯集信”或“乙方”)的通知,陳泳洪、黃智勇、黃利兵與中聯集信籤署了《〈表決權委託協議〉之補充協議》及《〈股東一致行動人協議〉之補充協議》,各方一致同意,將《表決權委託協議》及《股東一致行動人協議》的有效期均延長至2021年7月25日。
公司目前無控股股東及實際控制人,本次延長協議有效期不會改變公司無控股股東及實際控制人的現狀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.